Introduction
QVA149 is a once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium in development for the treatment of COPD. Here we present the symptom score results from three Phase III studies of QVA149.
Methods
All three studies were multicenter, double-blind, parallel-group, which randomized patients (pts) ≥40 yrs with moderate-to-severe COPD. E-diaries were provided to pts to record their daily symptoms.
Results
The SHINE, ENLIGHTEN and ILLUMINATE studies randomized 2144, 523 and 339 pts, respectively. QVA149 patients had statistically significant improvements in symptom scores compared with other treatment groups as shown in table.
View this table:
Table: Mean treatment difference in symptom scores
Conclusion
Once-daily QVA149 provides improvements in COPD symptoms compared to indacaterol, glycopyrronium, tiotropium and salmeterol/fluticasone.